ClinicalTrials.gg
Sign In
RecruitingNCT07918430Updated Nov 5, 2026

Primary Sac Abandonment and Distal Sac Fixation vs Complete Sac Dissection for Inguinoscrotal Hernias

An interventional study of Primary abondonment of sac and distal sac fixation and complete sac dissection in Seroma and Inguinal Hernias, sponsored by Kasr El Aini Hospital. Recruiting at 1 site in Egypt. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Kasr El Aini Hospital · Not applicable, Interventional, and Prevention

Updated Nov 5, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

The goal of this clinical trial is to compare the effect of primary abandonment of the sac and distal sac fixation vs complete sac dissection in patients with inguinoscrotal hernias undergoing trans abdominal pre-peritoneal (TAPP) procedure. The main questions it aims to answer are:

  1. The incidence of post-operative seroma.
  2. Difference in operative time
  3. Short-term hernia recurrence
02

Conditions studied

  • Seroma
  • Inguinal Hernias

Keywords

  • inguinoscrotal hernia
  • TAPP
  • Seroma
  • Distal sac fixation
03

In context

Seroma

101 studies on the registry are indexed under Seroma; 22 are open to participants now.

This study's planned enrollment of 60 is below the median of 100 across 92 interventional studies indexed under Seroma.

Browse Seroma studies →

Lead sponsor

Kasr El Aini Hospital is the lead sponsor of 287 studies on the registry; 34 are open to participants now.

Browse Kasr El Aini Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • inguinoscrotal hernias

Exclusion criteria

Exclusion Criteria:

  • Strangulated hernias
  • Recurrent inguinal hernias
  • Patients unfit for general anaesthesia and laparoscopy
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Primary sac abandonment and distal sac fixation

    Procedure: Primary abondonment of sac and distal sac fixation

  • Active comparator
    Complete sac dissection

    Procedure: complete sac dissection

Interventions

  • ProcedurePrimary abondonment of sac and distal sac fixation

    Primary abondonment of sac and distal sac fixation

  • Procedurecomplete sac dissection

    complete sac dissection

06

What researchers measure

Primary outcomes

  1. Seroma

    Post-operative scrotal collection

    Time frame: 30 days post-operatively

Secondary outcomes

  1. Operative time

    Time frame: Skin to skin operative time of the procedure

  2. Short term hernia recurrence

    Time frame: hernia recurrence 3 months after the procedure

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

Of 43 non-industry interventional studies with no phase under Seroma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 65. This study's planned 9 months is below that.

Counting every sponsor, half of 44 studies reached it within 34 months; a quarter within 17 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 5, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Aug 1, 2027
CompletionEst.
Oct 1, 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07918430
Lead sponsor
Kasr El Aini Hospital
Responsible party
Ayman Alayat (Ayman Alayat, Kasr El Aini Hospital) — Principal investigator
First posted
Nov 5, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Aug 1, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Tarek Salem Mabrouk
Contact
tareksalem2018011@gmail.com
00201143307034

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Seroma →

Other studies from this sponsor

Kasr El Aini Hospital →

Start the discussion